HSTA · Hestia Insight Inc.

Hestia Insight Inc. (HSTA) reported zero revenue and gross profit for Q1 FY2026 ended February 28, 2026, down 100% from $38K in the prior-year quarter. This topline pause aligns with the company's strategic shift through its wholly owned subsidiary Hestia Investments, which provides strategic consulting, medical supply sales support, management, and capital market advisory services to micro, small, and medium-sized healthcare and biotech firms. Management's focus on small and micro-cap companies with limited growth capital access, combined with building an ecosystem via acquisitions, licensing, joint ventures, and direct investments, explains the absence of billable consulting activity. The intentional revenue halt preserves margins at zero cost of revenue but extends a rebuild phase, where proprietary AI tools for fundraising and fractional C-suite support aim to differentiate in a crowded advisory market—though client acquisition delays could prolong zero-revenue periods.

Operating income improved markedly to -$39.3K from -$110.7K, a 64.5% reduction in loss magnitude. This stems primarily from decreased professional fees associated with becoming and remaining a public company, plus a company-wide emphasis on cost reduction. Such discipline demonstrates operational leverage even without revenue, narrowing losses through scalable overhead cuts rather than topline growth.

Net income flipped to a $3.2K profit from a -$392.3K loss, with diluted EPS at $0.001 versus -$0.001 prior year. This turnaround reflects the interplay of operating improvements and non-operating elements, positioning the company toward per-share positivity amid its pivot.

Cash flow from operations reflected heightened usage at -$36.8K, up modestly from -$36.0K, primarily due to the increase in operating expenses noted in management discussion—despite the net quarterly decline. This slight uptick underscores timing mismatches in expense payments even as overall costs trended lower.